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ABSTRACT 
INTRODUCTION 
Many patients want to stay at home to die. They invariably become unable to take 
oral medication during their terminal phase. Symptoms are usually controlled by 
subcutaneous medications. There have been no studies on nasal fentanyl (NF) or 
buccal midazolam (BM) to control symptoms in the dying. 
 
OBJECTIVE 
To establish how best to conduct a definitive, randomised controlled trial (RCT) to 
determine whether NF and BM administered by families, for patients dying at home, 
lead to faster and better symptom control and fewer community nursing visits than 
standard breakthrough medication by healthcare professionals. 
 
METHODS 
This open-label mixed methods feasibility RCT compared the efficacy of NF and BM 
by family members to standard breakthrough medication by nurses for the terminally 
ill in a specialist palliative care unit. Partway through the study, a third observational 
arm was introduced where BM alone was used. The primary outcomes were whether 
recruitment and randomisation were possible, assessment of withdrawal and drop-
out, and whether the methods were acceptable and appropriate. 
 
RESULTS 
Administration of NF and BM was acceptable to patients and families. Both were well 
tolerated. We were unable to obtain quality of life data consistently but did get time 
period data for dose-controlled symptoms. 
4 
 
CONCLUSIONS 
Study participation in a hospice population of the dying was acceptable. The results 
will help guide future community study planning. 
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INTRODUCTION 
People with terminal illnesses need timely symptom control and should be able to die 
in their ‘preferred place of care’1 (usually home2). Dying patients are often too weak 
to take oral medication.  The mainstay in the United Kingdom (UK) is subcutaneous 
infusions by syringe driver and top-up medication by subcutaneous injection3. Family 
carers can be trained to give injections 4-6. In the UK, this is less common. Usually, 
when the terminally ill experience symptoms, a carer calls a community nurse for an 
injection. It can take hours for nurses to arrive7. This is often distressing for patients 
and families.  
 
In 2015 the Palliative Care and end of life care Priority Setting Partnership published 
results.  It used surveys and a prioritisation workshop with patients, carers and 
professionals, to identify the top 10 unanswered research questions in palliative/end 
of life care. Symptom concerns, unscheduled hours, and family support were given 
priority8.  
 
There can be disquiet about injections9,10. There are alternative preparations given 
more rapidly and easily – (both fast acting) nasal fentanyl (NF) and buccal 
midazolam (BM). Research has examined NF for breakthrough pain11 and BM for 
seizures12 but not in the dying. In preparation for a community randomised trial of 
these administration modes, we assessed study methodology. 
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METHODS 
We started recruitment to a randomised controlled trial from December 2016 but 
gained approval to recruit an additional third observational arm of BM alone from 
October 2017. All patients could receive standard as needed medication.  Hospice 
inpatients and carers fitting inclusion criteria were identified as possible participants 
by the clinical team. If the patient had capacity, the study was discussed with them 
first and then their carer. Where they lacked capacity, the study was discussed with 
carer only. 
Abbreviated Inclusion Criteria: 
• Hospice inpatients 
• Terminal cancer; estimated prognosis 1-2 weeks 
• Carer/family member willing to give medication AND likely to be at the hospice at 
least 25% of the time 
 
Study Procedures 
Three patient information leaflets AND consent forms were used for: 1) Patients with 
capacity; 2) Carers; 3) Carers willing to consent on behalf of patients lacking 
capacity. Potential participants were given information leaflets. After as much time as 
they wished, they were asked to sign appropriate consent forms.  Patients eligble for 
Groups A and B were randomised via telephone by the sponsoring hospital 
Research Support Service:   
• Group A – NF replaced subcutaneous opioids for pain and BM subcutaneous 
benzodiazepine for agitation. Group A could receive NF four hourly; up to four 
times daily on a titration schedule. Once effectively titrated, carers could also 
administer BM four hourly; up to four times daily.  
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• Group B – Standard Care – oral, sublingual, or subcutaneous medication 
(anti-emetics, anti-secretory drugs, benzodiazepines and opioids). 
• Patients eligible for Group C – BM replaced subcutaneous benzodiazepine for 
agitation.  Group C could receive BM four hourly; up to four times daily. 
Nursing staff could administer trial medication if carers were not present OR not 
confident. 
Carers in Groups A and C received Symptom Management Training Packs about 
symptom assessment and training on how to use trial drugs: 
NF and BM – Group A 
BM alone – Group C 
 
Outcome Measures 
The following were collected: 1) time to adequate symptom control; 2) need for 
additional medication; 3) adverse events; 4) time to onset; 5) time from dose to 
symptom recurrence.  
Symptoms were measured by the modified Palliative Care Outcome Scale – 
symptom module (POS-S)13 daily. After agreement from Dr Fliss Murtagh (then 
Reader and Consultant in Palliative Medicine at King’s College, London), we 
removed the question on ‘any other symptoms?’ and added the anxiety question 
from the Integrated Palliative care Outcome Scale (IPOS). 
 
Adverse Events 
As a study in the terminally ill, it was expected death would be frequent. It was 
reported to the sponsor, but not considered a serious adverse event if, in the Chief 
Investigator’s opinion, it was a natural conclusion to the illness. Deaths did not 
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require immediate reporting to the Medicines and Healthcare products Regulatory 
Agency (MHRA) or Ethics Committee.  
 
Statistical Analysis 
For all quantitative outcome measures, the main aim was feasibility of intervention 
delivery to help design a main trial.  Indicative outcomes were underpowered for 
statistical interpretation. 
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RESULTS 
There were 337 hospice admissions during the study period (320 individuals). 308 
did not meet inclusion criteria. Main reasons not terminally ill; not on a high enough 
background opioid dose; family not present 25% of the time. Of the 29 eligible 
patients/carers approached, 9 declined. Of the 20 patients enrolled, 3 completed the 
study, 8 died, and 9 withdrew (family request – 4; adverse event – 2; unable to titrate 
NF – 2; discharged home - 1).  Of 9 in Arm A, 1 died before study drug and 2 
withdrew because they could not be titrated on NF (i.e. pain uncontrolled 30 minutes 
after 800mcg dose). All 9 in Arm B received symptom-relieving medication. Of the 2 
in Arm C, 1 did not receive study drug. There were 308 breakthrough episodes 
requiring medication: Arm A – 165; Arm B – 125; Arm C – 18. There were 85 doses 
of experimental drug given; 41 post-titration. 
 
Median time from recruitment to death was 7 days; 1 patient lived 119 days. In Arm 
A, the successful NF dose was 100mcg for 2; 200mcg for 3; 400mcg for 1. Of the 3 
given BM (Arms A and C), all responded to 2.5mg.  There were missing data for 
outcome measures but none for dose timing. Results are in Table 1 for the 6 
titratable patients in Arm A, 9 Arm B, and 1 in Arm C who received trial medication. 
Those successfully titrated on study drugs had faster and longer lasting symptom 
control than standard medication.  
 
Adverse Events 
There was one serious adverse event (wrong dose of study drug).  
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DISCUSSION 
It was possible to conduct a feasibility study in a single hospice. When we planned 
this study, carers administering symptom medications at home were rare. It was 
thought safer to conduct a feasibility study in a controlled environment. In the years it 
took to finalise the protocol, secure funding and approvals, a multi-centre, feasibility, 
community randomised trial has been conducted comparing subcutaneous 
medication administered by families versus healthcare professionals14. 
 
It was expected many admissions would be ineligible. Half of the unit’s admissions 
go home. Often the families of those admitted are unable to provide care (or would 
not be present 25% of the time). Patient/family distress or likely inability to safely 
administer drug were issues in a few. Families approached often wanted the 
opportunity to give medication. A future community study would only approach 
terminal patients wanting to stay at home (perhaps making recruitment easier). 
Recruitment time was limited by a short expiry date for BM. A substantial 
amendment was approved for an observational Arm C (BM alone as experimental 
drug). This led to two patients recruited and while one did not receive study 
medication, the other did receive symptomatic benefit.  There was much missing 
data. We were wary of burdening patients, families, and busy staff. As the study 
required caregivers to be present 25% of the time, we anticipated missing data for 
family assessments. There was much missing nursing assessment data despite 
research team support including training sessions and 24-hour research team 
advice.  
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The drugs were largely well tolerated. Of concern was the wrong dose of NF on 
three occasions by nursing staff; in one incident, four times the correct dose.  We 
classified this as a serious adverse event. The patient was sleepier but otherwise 
unharmed. No errors were made by families and these incidents confirm how 
important training and 24-hour support would be in a potential community study. For 
a future community study, dose timing, number of doses used, and need for rescue 
medication from community nurses would be the best outcome measures.  
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CONCLUSIONS: 
We hope to use lessons from this research to plan studies to investigate how best to 
support patients dying at home and their families. One would expect those in a 
specialist palliative care unit to have the most complex symptoms and families 
struggling to cope with home care. A future community study would likely recruit 
more ‘normal dying’ with easier to treat symptoms and families more able to help. 
Our study showed that even amongst the most complex illnesses, patients and 
families are happy to participate.  
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TABLE 1: PRIMARY AND SECONDARY OUTCOMES 
 
Outcomes 
Median Time: Minutes (Interquartile Range) 
Experimental Drugs 
Post-Titration (Arms A,     
C – 41 Episodes) 
Standard Drugs (Arms 
A, B, C – 223 Episodes) 
Primary Outcomes   
Time to symptom control from 
when needed 
20 (17.5 – 29.0) 30 (25.0 – 38.0) 
Time from medication to onset 
of symptom control   
10 (9.0 – 16.0) 20 (16.0 – 30.0) 
Secondary Outcome   
Time from medication to next 
breakthrough medication 
380 (142.5 – 694.0) 275 (152.5 – 537.5) 
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